Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Study of Cancer Therapy Induced Thrombocytopenia in China
ChiCTR2200066614Phase 4Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Sep 2022
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recombinant human thrombopoietin, oprelvekin, eltrombopag, avatrombopag and hetrombopag in Thrombocytopenia, sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Disease characteristics and treatment patterns of cancer therapy induced thrombocytopenia. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietinoprelvekineltrombopagavatrombopaghetrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on ChiCTR2200066614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066614.